Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg slightly lowers target price on Pan African Resources

(Sharecast News) - Analysts at Berenberg slightly lowered their target price on gold producer Pan African Resources from 42.0p to 39.0p on Thursday as they rebased their stance on the stock following the publication of its H1 numbers. Pan African shares closed down roughly 3.6% on Wednesday and took the weekly drop to around 14%, having sold off on 10 February following the release of a H1 trading statement that guided for lower earnings.

Berenberg stated the quantum of the selloff was, in its view, a reflection of "a stellar share price performance" over the past 12 months and "perhaps some profit taking".

The German bank noted that the results themselves flagged cost pressure in Pan African's two underground assets in South Africa, with management working to cut costs at these assets.

"Still, these assets are higher cost than the low-cost surface deposits that comprise the majority of production," noted Berenberg. "While Barberton and Evander should generate decent cash flow in H2 and beyond at current elevated gold prices, we think that investors want to see costs coming lower at these assets and look for demonstrable signs of this."

Berenberg adjusted its model for the H1 results and made some "conservative adjustments" to expenses given higher costs at mines like Barberton and Evander.

"We lift our EV/EBITDA multiple to 4.5x (from 3.9x) to reflect portfolio growth not exhibited in current multiples, but adjusted forecasts and a softer NAV sees our price target move to 39.0p per share. We remain 'buy'-rated, with the shares trading on 1.15x NAV and 2.3x FY26E EBITDA, but H2 needs to be a half of delivery."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.